

## **ASX ANNOUNCEMENT**

### **AdAlta and La Trobe awarded SIEF Business Fellowship grant to identify novel i-bodies**

**MELBOURNE Australia, 24 July, 2017:** AdAlta Limited (ASX:1AD), the biotechnology Company advancing its lead i-body candidate towards clinical development today announced the awarding of a Science and Industry Endowment Fund (SIEF) Business Fellowship to Dr Chris Hosking, further strengthening the collaboration between AdAlta and La Trobe University.

The SIEF Business Fellowship Program aims to build deeper connections and collaborations between researchers and industry, accelerate the adoption of new ideas and technology while also helping businesses to grow into larger and more profitable organisations. Furthermore, the program provides practical industry experience for early career researches.

AdAlta Chief Executive Officer Sam Cobb said: "This SIEF Fellowship provides non-dilutive funding to facilitate further development of our i-body pipeline".

The fellowship will support Dr Chris Hosking's work with Prof Mick Foley, AdAlta Chief Scientific Officer, at the La Trobe Institute for Molecular Science. The Fellowship will give Dr Chris Hosking and AdAlta the opportunity to focus on identifying potential new clinical candidates from AdAlta's proprietary i-body library, the platform technology that will drive future assets and commercial opportunities. The Fellowship will provide a total of \$427,000 funding (\$210,000 from CSIRO).

Professor Mick Foley said: "Under the SIEF grant we will screen the i-body library to identify and develop new i-body candidates against difficult to access drug targets such as complex signalling proteins called GPCRs. Chris is an excellent candidate for the fellowship because he has extensive experience working with phage displays and screening libraries. Chris brings significant expertise to the AdAlta team."

Dr Daniel Grant, La Trobe Pro Vic Chancellor Industry and Engagement, said: "La Trobe recognises the importance of engaging with, and building strong partnerships with, innovative companies. We have had a longstanding and productive relationship with AdAlta and this Fellowship is a great outcome for both parties."

## **Notes to Editors**

### **About AdAlta**

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, which was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: [www.adalta.com.au](http://www.adalta.com.au).

**For more information, please contact:**

**AdAlta Limited**

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: [s.cobb@adalta.com.au](mailto:s.cobb@adalta.com.au)